TALEN® technology (Transcription Activator-Like Effector Nuclease)

	Next higher product group	nucleic acid editing technology (DNA/RNA-editing technology)
	Status	2011-02-28 sales existent
	Organisation	Cellectis Bioresearch SAS
	Group	Cellectis (Group)

Record changed: 2023-07-10

Picture EBD Group BIO-Europe 2026 Köln Cologne to 31 Jul 650x200px

More documents for TALEN® technology (Transcription Activator-Like Effector Nuclease)

[1] Cellectis S.A.. (12/28/22). "Press Release: Cellectis Secures a €40 Million Credit Facility from the European Investment Bank to Support its Research, Development and Innovation Activities". Paris....
[2] Cellectis S.A.. (2/16/21). "Press Release: Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells". Cambridge, MA & New York, NY....
[3] Cellectis S.A.. (4/13/20). "Press Release: Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer". New York, NY....
[4] Cellectis S.A.. (1/12/20). "Press Release: Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement". San Carlos, CA & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)